Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells

Journal of the American Society of Nephrology

Volumn 15, Issue 9, 2004, Pages 2258-2265

  Sidaway, James E ^a   Davidson, Robert G ^b   McTaggart, Fergus ^b   Orton, Terry C ^a   Scott, Robert C ^a   Smith, Graham J ^b   Brunskill, Nigel J ^c  

^a ASTRAZENECA   (United Kingdom)

^b Cardiovasc and Gastrointest Dept   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATORVASTATIN; BETA 2 MICROGLOBULIN; CHOLESTEROL; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPOPROTEIN; MEVALONIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANIMAL CELL; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENDOCYTOSIS; ENZYME MECHANISM; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; NONHUMAN; OPOSSUM; PRENYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TRANSPORT; RECEPTOR INTRINSIC ACTIVITY;

EID: 4344667844     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000138236.82706.EE     Document Type: Article

References (48)

1. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990
2. Tobert JA: Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2: 517-526, 2003
3. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92: 152-160, 2003
4. Caslake MJ, Stewart G, Day SP, Daly E, McTaggart F, Chapman MJ, Durrington P, Laggner P, Mackness M, Pears J, Packard CJ: Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 171: 245-253, 2003
5. Ma PT, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS: Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoproteins in livers of hamsters and rats. Proc Natl Acad Sci U S A 83: 8370-8374, 1986
6. Kovanen PT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS: Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci U S A 78: 1194-1198, 1981
7. Goldstein JL, Brown MS: Regulation of low-density lipoprotein receptors: Implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 76: 504-507, 1987
8. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC: Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20: 2761-2771, 2000
9. Park HJ, Galper JB: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci U S A 96: 11525-11530, 1999
10. Stark WW Jr, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P: Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol 275: L55-L63, 1998
11. Leonard S, Beck L, Sinensky M: Inhibition of isoprenoid biosynthesis and the post-translational modification of pro-p21. J Biol Chem 265: 5157-5160, 1990
12. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: 285-288, 2002
13. Roskoski R Jr: Protein prenylation: a pivotal posttranslational process. Biochem Biophys Res Commun 303: 1-7, 2003
14. Zerial M, McBride H: Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2: 107-117, 2001
15. Clague MJ: Molecular aspects of the endocytic pathway. Biochem J 336: 271-282, 1998
16. Crestor [package insert]. Wilmington, DE, AstraZeneca, 2003
17. Brewer HB Jr: Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 92: 23K-29K, 2003
18. Olsson AG, McTaggart F, Raza A: Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 20: 303-328, 2002
19. Christensen EI, Birn H: Megalin and cubilin: Synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 280: F562-F573, 2001
20. Malstrom K, Stange G, Murer H: Identification of proximal tubular transport functions in the established kidney cell line, OK. Biochim Biophys Acta 902: 269-277, 1987
21. Gekle M, Mildenberger S, Freudinger R, Schwerdt G, Silbernagl S: Albumin endocytosis in OK cells: Dependence on actin and microtubules and regulation by protein kinases. Am J Physiol 272: F668-F677, 1997
22. Brunskill NJ, Stuart J, Tobin AB, Walls J, Nahorski S: Receptor-mediated endocytosis of albumin by kidney proximal tubule cells is regulated by phosphatidylinositide 3-kinase. J Clin Invest 101: 2140-2150, 1998
23. Brunskill NJ, Cockcroft N, Nahorski S, Walls J: Albumin endocytosis is regulated by heterotrimeric GTP-binding protein G alpha i-3 in opossum kidney cells. Am J Physiol 271: F356-F364, 1996
24. Verhulst A, D'Haese PD, DeBroe ME: Statins inhibit proximal tubular cell endocytosis. J Am Soc Nephrol 15: 2249-2257, 2004
25. McTaggart F, Brown GR, Davidson RG, Freeman S, Holdgate GA, Mallion KB, Mirrlees DJ, Smith GJ, Ward WH: Inhibition of squalene synthase of rat liver by novel 3′ substituted quinuclidines. Biochem Pharmacol 51: 1477-1487, 1996
26. Schwegler JS, Heppelmann B, Mildenberger S, Silbemagl S: Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: A model for proximal tubular protein reabsorption. Pflugers Arch 418: 383-392, 1991
27. Lebeau C, Arlt VM, Schmeiser HH, Boom A, Verroust PJ, Devuyst O, Beauwens R: Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int 60: 1332-1342, 2001
28. Brunskill NJ, Nahorski S, Walls J: Characteristics of albumin binding to opossum kidney cells and identification of potential receptors. Pflugers Arch 433: 497-504, 1997
29. Staal A, Frith JC, French MH, Swartz J, Gungor T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH: The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18: 88-96, 2003
30. Suzuki N, Urano J, Tamanoi F: Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A 95: 15356-15361, 1998
31. Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD: Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem 42: 1333-1340, 1999
32. Choi JS, Kim KR, Ahn DW, Park YS: Cadmium inhibits albumin endocytosis in opossum kidney epithelial cells. Toxicol Appl Pharmacol 161: 146-152, 1999
33. Takano M, Nakanishi N, Kitahara Y, Sasaki Y, Murakami T, Nagai J: Cisplatin-induced inhibition of receptor-mediated endocytosis of protein in the kidney. Kidney Int 62: 1707-1717, 2002
34. Farquhar MG, Kerjaschki D, Lundstrom M, Orlando RA: gp330 and RAP: The Heymann nephritis antigenic complex. Ann N Y Acad Sci 737: 96-113, 1994
35. Christensen EI, Willnow TE: Essential role of megalin in renal proximal tubule for vitamin homeostasis. J Am Soc Nephrol 10: 2224-2236, 1999
36. Brown D, Stow JL: Protein trafficking and polarity in kidney epithelium: From cell biology to physiology. Physiol Rev 76: 245-297, 1996
37. Gekle M, Mildenberger S, Freudinger R, Silbernagl S: Kinetics of receptor-mediated endocytosis of albumin in cells derived from the proximal tubule of the kidney (opossum kidney cells): Influence of Ca2+ and cAMP. Pflugers Arch 430: 374-380, 1995
38. Sasaki Y, Nagai J, Kitahara Y, Takai N, Murakami T, Takano M: Expression of chloride channel, ClC-5, and its role in receptor-mediated endocytosis of albumin in OK cells. Biochem Biophys Res Commun 282: 212-218, 2001
39. Sinensky M: Recent advances in the study of prenylated proteins. Biochim Biophys Acta 1484: 93-106, 2000
40. Lamaze C, Chuang T-H, Terlecky LJ, Bokoch GM, Schmid SL: Regulation of receptor-mediated endocytosis by Rho and Rac. Nature 382: 177-179, 1996
41. Holdgate GA, Ward WH, McTaggart F: Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 31: 528-531, 2003
42. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87: 28B-32B, 2001
43. Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29: 239-243, 1990
44. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T: Absolute oral bioavailability of rosuvastatin in healthy white male volunteers. Clin Ther 25: 2553-2563, 2003
45. Sauvant C, Holzinger H, Gekle M: Modulation of the basolateral and apical step of transepithelial organic anion secretion in proximal tubular opossum kidney cells. Acute effects of epidermal growth factor and mitogen-activated protein kinase. J Biol Chem 276: 14695-14703, 2001
46. Kusuhara H, Sugiyama Y: Role of transporters in the tissue-selective distribution and elimination of drugs: Transporters in the liver, small intestine, brain and kidney. J Control Release 78: 43-54, 2002
47. McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab 87: 1451-1458, 2002
48. Brunskill NJ: Albumin and proximal tubular cells-beyond endocytosis. Nephrol Dial Transplant 15: 1732-1734, 2000